LNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lantheus Holdings Inc (LNTH) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising long-term growth prospects and analyst ratings are positive, the recent financial performance shows significant declines in net income, EPS, and gross margin. Additionally, insider and hedge fund selling trends indicate negative sentiment. The technical indicators suggest a neutral to slightly bullish trend, but without strong proprietary trading signals or immediate catalysts, it is better to hold off for now.
The MACD is positive and contracting, RSI is neutral at 58.441, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of 82.451, with resistance at 84.468 and support at 80.434. The technical indicators suggest a neutral to slightly bullish trend.
Analysts have raised price targets recently, with Truist, Mizuho, and Jefferies projecting targets between $95 and $
Strong demand for medical imaging solutions and recent FDA approvals have driven a 23% YTD stock price increase.
Promising long-term growth prospects, particularly with PYLARIFY and PSMA PET market expansion.
Hedge funds and insiders are selling heavily, with insider selling up 5211.12% in the last month.
Financial performance in Q4 2025 shows significant declines in net income (-558.76% YoY), EPS (-576.47% YoY), and gross margin (-6.83% YoY).
No recent congress trading data or strong proprietary trading signals to support immediate action.
In Q4 2025, revenue increased by 4.01% YoY to $406.79M, but net income dropped significantly by -558.76% YoY to $54.09M. EPS also declined by -576.47% YoY to 0.81, and gross margin fell to 59.21%, down -6.83% YoY. The financials indicate declining profitability despite revenue growth.
Analysts are generally positive on LNTH, with recent upgrades and raised price targets. Truist, Mizuho, and Jefferies have raised their price targets to $98, $95, and $110, respectively, citing strong long-term growth prospects and product expansions. However, JonesResearch downgraded the stock to Hold, citing limited short-term revenue contributions from radiotherapeutic assets.
